Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

医学 乳腺癌 肿瘤科 内科学 化疗 新辅助治疗 三阴性乳腺癌 阶段(地层学) 肿瘤浸润淋巴细胞 癌症 免疫疗法 生物 古生物学
作者
Carsten Denkert,Gϋnter von Minckwitz,Silvia Darb‐Esfahani,Bianca Lederer,Barbara Ingold Heppner,Karsten E. Weber,Jan Budczies,Jens Huober,Frederick Klauschen,Jenny Furlanetto,Wolfgang Schmitt,Jens‐Uwe Blohmer,Thomas Karn,Berit M. Pfitzner,Sherko Kümmel,Knut Engels,Andreas Schneeweiß,Arndt Hartmann,Aurelia Noske,Peter A. Fasching
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (1): 40-50 被引量:1733
标识
DOI:10.1016/s1470-2045(17)30904-x
摘要

Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer.Patients with primary breast cancer who were treated with neoadjuvant combination chemotherapy were included from six randomised trials done by the German Breast Cancer Group. Pretherapeutic core biopsies from 3771 patients included in these studies were assessed for the number of stromal TILs by standardised methods according to the guidelines of the International TIL working group. TILs were analysed both as a continuous parameter and in three predefined groups of low (0-10% immune cells in stromal tissue within the tumour), intermediate (11-59%), and high TILs (≥60%). We used these data in univariable and multivariable statistical models to assess the association between TIL concentration and pathological complete response in all patients, and between the amount of TILs and disease-free survival and overall survival in 2560 patients from five of the six clinical trial cohorts.In the luminal-HER2-negative breast cancer subtype, a pathological complete response (pCR) was achieved in 45 (6%) of 759 patients with low TILs, 48 (11%) of 435 with intermediate TILs, and 49 (28%) of 172 with high TILs. In the HER2-positive subtype, pCR was observed in 194 (32%) of 605 patients with low TILs, 198 (39%) of 512 with intermediate TILs, and 127 (48%) of 262 with high TILs. Finally, in the TNBC subtype, pCR was achieved in 80 (31%) of 260 patients with low TILs, 117 (31%) of 373 with intermediate TILs, and 136 (50%) of 273 with high TILs (p<0·0001 for each subtype, χ2 test for trend). In the univariable analysis, a 10% increase in TILs was associated with longer disease-free survival in TNBC (hazard ratio [HR] 0·93 [95% CI 0·87-0·98], p=0·011) and HER2-positive breast cancer (0·94 [0·89-0·99], p=0·017), but not in luminal-HER2-negative tumours (1·02 [0·96-1·09], p=0·46). The increase in TILs was also associated with longer overall survival in TNBC (0·92 [0·86-0·99], p=0·032), but had no association in HER2-positive breast cancer (0·94 [0·86-1·02], p=0·11), and was associated with shorter overall survival in luminal-HER2-negative tumours (1·10 [1·02-1·19], p=0·011).Increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed, and was also associated with a survival benefit in HER2-positive breast cancer and TNBC. By contrast, increased TILs were an adverse prognostic factor for survival in luminal-HER2-negative breast cancer, suggesting a different biology of the immunological infiltrate in this subtype. Our data support the hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies. In light of the results in luminal breast cancer, further research investigating the interaction of the immune system with different types of endocrine therapy is warranted.Deutsche Krebshilfe and European Commission.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
anna发布了新的文献求助10
1秒前
勤奋梨愁发布了新的文献求助10
2秒前
2秒前
潘善若发布了新的文献求助10
2秒前
momo发布了新的文献求助10
3秒前
3秒前
7秒前
9秒前
诺奇完成签到,获得积分10
11秒前
潘善若发布了新的文献求助10
13秒前
乖猫要努力应助猪猪hero采纳,获得10
13秒前
16秒前
16秒前
科目三应助不学无术采纳,获得10
16秒前
MrSong完成签到,获得积分10
20秒前
20秒前
momo发布了新的文献求助10
20秒前
小曾应助安静的万声采纳,获得10
21秒前
高贵的飞阳完成签到,获得积分10
21秒前
小梦发布了新的文献求助10
22秒前
22秒前
23秒前
科研通AI5应助GooJohn采纳,获得10
24秒前
Ava应助yyy采纳,获得10
28秒前
善学以致用应助yyy采纳,获得10
28秒前
共享精神应助yyy采纳,获得10
28秒前
李健的小迷弟应助yyy采纳,获得10
28秒前
JamesPei应助yyy采纳,获得10
28秒前
共享精神应助yyy采纳,获得10
28秒前
潘善若发布了新的文献求助10
28秒前
LL完成签到,获得积分10
29秒前
hu完成签到,获得积分10
31秒前
31秒前
32秒前
久久应助CSPC001采纳,获得10
33秒前
TaoBijiang完成签到,获得积分10
34秒前
34秒前
善学以致用应助勤奋梨愁采纳,获得10
35秒前
loststarts应助yyy采纳,获得10
35秒前
科研助手6应助yyy采纳,获得10
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136